samedan logo
 
 
 
spacer
home > ebr > autumn 2020 > how pharma can conquer the next pandemic
PUBLICATIONS
European Biopharmaceutical Review

How Pharma Can Conquer the Next Pandemic

The COVID-19 pandemic has brought a level of global disruption unseen in most of our lifetimes, with countries around the world continuing to grapple with infection rates and lockdown restrictions.

While we’re still some way away from a realistic end to the crisis, we are starting to see some positive developments rising from the gloom: countries in Europe and Asia are seeing their mitigation and suppression efforts starting to bear fruit, and track and trace systems have been implemented and are improving in efficacy by the day. Treatments, and our general understanding of the virus, are also progressing, with dexamethasone emerging as a viable treatment for the sickest patients. Meanwhile, early clinical trials of several different vaccines have had promising results.

Unsurprisingly, the pharmaceutical industry has led the charge in the battle against COVID-19 in many respects, and will continue to be at the forefront of the global response in the months to come. Given the upheaval that the current outbreak has caused, the way the world responds will act as a blueprint for future pandemics. With this in mind, the pharma industry must learn as many valuable lessons from the situation as possible.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Vladimir Tkachenko, a pharmaceutical sciences expert, is General Manager of Amaxa Pharma, a UK-headquartered pharma company focused on life-threatening therapeutic areas such as oncology and neonatology in the Commonwealth of Independent States countries. Within this role, Vladimir is responsible for the general management and success of the company, developing sales strategy, implementing managerial accounting strategy, preparing operation budgets and licensing. Since joining Amaxa Pharma in 2012, Vladimir has been instrumental in its success in Europe, driving effective partnerships and bringing life-changing prescription and non-prescription medicines for the treatment of patients suffering from cancer, blood-related diseases, premature birth, and other life-threatening illnesses.
spacer
Vladimir Tkachenko
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Europital forecast 30% CAGR from UK biotech for three years

Europital – the global provider of medical management services for clinical research and drug development – announces it is opening a UK site to further expand its services to the UK biotech industry.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 1st Quarter 2014

Synergy Research Group

In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 
Industry Events

BIO-Europe Digital

26-29 October 2020, Digitally delivered

Global connections are more important than ever. With the same powerful one-to-one partnering and valuable content, BIO-Europe Digital continues to help you drive your life science partnering forward.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement